Patrick Phillips

Patrick Phillips is an Associate Professor and Co-Director of the UC TRAC Clinical & Population Health Science Core at the University of California, San Francisco (UCSF). His research focuses on optimizing clinical trials for tuberculosis (TB) treatments, particularly drug-sensitive and drug-resistant forms. He has led analyses of pivotal trials such as REMoxTB and RIFAQUIN, published in the New England Journal of Medicine. Phillips is a Senior Statistician for ongoing trials like STREAM for multidrug-resistant TB and has pioneered adaptive designs, including Multi-Arm Multi-Stage (MAMS) trials. His work extends to trials in Alzheimer’s and HIV, emphasizing global health significance.

As part of the UCSF Center for Tuberculosis Leadership & Initiatives, he contributes to strategies like TB RAMP Mentorship and the SMART4TB program. Phillips collaborates with global consortia, advancing TB treatment through statistical rigor and innovative trial methodologies. His expertise in biostatistics and clinical trial design has shaped protocols for high-dose rifampicin and novel drug combinations.

Key articles focus on treatment regimens, biomarker development (e.g., molecular bacterial load assays), and diagnostic accuracy studies using CRP and Xpert TB host response tests. He advocates for patient-centered approaches and has evaluated implementation strategies for preventive therapies like 3HP. Phillips’ work underscores optimizing treatment durations through risk-stratified approaches, aiming to balance efficacy and safety while addressing global TB challenges.